Azelaprag
BioAge Labs Halts Phase 2 Obesity Trial Due to Liver Safety Concerns Just Two Months After IPO
BioAge Labs, Phase 2 trial, obesity, liver safety concerns, azelaprag, Eli Lilly, tirzepatide, IPO
BioAge Labs Discontinues Phase II Obesity Study Due to Safety Concerns, Stock Plummets
BioAge Labs, azelaprag, obesity treatment, Phase II study, safety concerns, liver transaminitis, stock crash
BioAge Labs Files for IPO to Advance Obesity Treatment Candidate
BioAge Labs, IPO, obesity treatment, weight loss drugs, azelaprag, Eli Lilly, cardiometabolic biotech
BioAge Labs Files for $100 Million IPO to Advance Obesity Treatment Candidate Azelaprag
BioAge Labs, IPO, Obesity Treatment, Azelaprag, Eli Lilly, Novo Nordisk, Clinical Trials